2 result(s) found
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
https://www.zacks.com/stock/news/2236241/fda-lifts-clinical-hold-on-iovance-s-iova-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236241
Mar 05, 2024 - The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
0
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
https://www.zacks.com/stock/news/2203219/iovance-iova-falls-after-clinical-update-on-lung-cancer-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2203219
Dec 28, 2023 - Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
0
Pages: 1
Page 1